App-Quantinova.ai

Real-world single-centre experience of JAK inhibitor use in RA

Aqeel Maqsood Anjum - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Attitudes to technology-supported rheumatoid arthritis care, questionnaire study: opportunities for technology to improve RA care

Amy MacBrayne - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Self-care for rheumatoid arthritis during the COVID-19 pandemic: transferability of Canadian and UK experiences

James Gavin - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Rheumatoid arthritis

N/A

Predictive factors for successful biologic disease-modifying anti-rheumatic drugs dose tapering in rheumatoid arthritis

Min Yi Loh - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

To investigate the mechanisms of action of novel compounds ex vivo in cells obtained from the inflammatory synovium of patients with rheumatoid arthritis

Madeleine Turner - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

Advanced therapies in patients with rheumatoid arthritis in moderate disease activity: a single-centre experience

Frances Humby - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Catheter-related venous thrombosis in patients with systemic sclerosis: a case series

Chiara Giacomassi - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Scleroderma

N/A

Effectiveness of intravenous belimumab in patients with systemic lupus erythematosus at a UK tertiary referral centre

Garry Mallett - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prednisolone

A review of the development of gangrene in patients with systemic lupus erythematosus: a 44-year follow-up study

Joana Rua - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

A UK review of the use of MRI in the diagnosis of axial SpA

Timothy J Bray - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Analysis of the Early Inflammatory Back Pain Clinic at the Royal National Hospital for Rheumatic Diseases

Matthew Cowan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Investigating the relationship between daily disease impact scores and mood in patients with psoriatic arthritis using a smartphone application: a novel use of the PsAID-9 questionnaire

Dylan McGagh - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Comparing ankylosing spondylitis disease activity during the COVID-19 pandemic using patient-reported outcome measures with face-to-face clinical evaluation of disease scores pre-pandemic

Dominik A Kurzeja - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Ankylosing spondylitis

N/A

Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial

Philip G Conaghan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis

Bruce Strober - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

guselkumab (IV)

Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Non-radiographic axial spondyloarthritis

secukinumab

Secondary care collaborative service to reduce time to diagnosis in axial spondyloarthropathy: retrospective study from Leicester combined rheumatology-uveitis service

Ameen Jubber - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Spondyloarthritis

N/A

Improving recognition and referrals for axial spondyloarthritis in primary care

Daniel Hamilton - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Confirmatory factor analyses of the Tampa Scale of Kinesiophobia 11-item version and Pain Catastrophising Scale: A cross-sectional study in people living with axial spondyloarthritis

Peter C Rouse - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

The effect of new classification criteria on the diagnosis of large vessel vasculitis

Chetan B Mukhtyar - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Large vessel vasculitis

N/A

Filters

45280 Abstracts